Mumbai, Maharashtra, India:GlaxoSmithKline Pharmaceuticals Limited has announced its financial results for the third quarter ended 30th September 2012. The growth in Net Sales was 10% and Profit After Tax and before Exceptional Items was 12%. The core Pharmaceuticals business grew by 11% during the quarter.
During the quarter, the Company launched Zimivir for herpes treatment. The Company expanded its CNS portfolio by launching Ictacetam used in the treatment of epilepsy.
Commenting on the performance Dr. Hasit Joshipura, Managing Director, said “The vaccines business continues to record strong growth. The quarter also saw good growth across verticals, in particular, Specialities. Sales were impacted due to constraints of sterile manufacture owing to shutdown of one of the suppliers, as well as, on account of constraints at the Nashik facility. These constraints have since been resolved”.
GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit www.gsk-india.com .
To view the results please click on the link given below:
Statement of Standalone Unaudited Results for the Quarter and Nine Months ended September 30, 2012
Nandini Goswami, General Manager, Corporate Communications, , +91 (22) 24959203